Managing Crohn’s disease means combining the right medications with dietary adjustments, regular monitoring, and attention to your mental health. About 25% of people with Crohn’s still need surgery within 10 years of diagnosis, but that number has been declining as treatments improve and doctors move toward earlier, more aggressive therapy. The goal today isn’t just controlling symptoms. It’s healing the intestinal lining itself, which reduces hospitalizations, surgeries, and long-term complications.
Why Early, Aggressive Treatment Matters
For years, the standard approach was “step-up” therapy: start with milder drugs and escalate only when they failed. The 2025 guidelines from the American College of Gastroenterology now recommend against this for moderate-to-severe disease. New evidence shows that starting advanced therapies early produces better outcomes than waiting for conventional drugs to fail. If your doctor suggests a biologic or another advanced medication soon after diagnosis, that’s in line with current best practice.
Mesalamine, once widely prescribed, is now strongly discouraged for Crohn’s because it simply doesn’t work well enough. Sulfasalazine is only considered for mild disease limited to the colon. Budesonide, a targeted steroid, remains useful for bringing mild-to-moderate disease under control in the area where the small intestine meets the colon, but it’s not meant for long-term use.
Medications for Moderate-to-Severe Disease
Systemic steroids (like prednisone) are still used to quickly tamp down a flare, but guidelines strongly recommend limiting them to fewer than three months with a structured taper. They’re a bridge, not a destination. The real work of keeping Crohn’s in remission falls to steroid-sparing medications.
The medication landscape has expanded significantly. Anti-TNF drugs work by shutting down a key inflammatory signaling molecule and prompting certain immune cells in the gut lining to self-destruct. They remain a cornerstone of treatment and have proven track records for healing the intestinal lining, reducing surgeries, and getting people off steroids. Newer options target a different part of the immune system: IL-23 inhibitors block a protein that drives chronic gut inflammation. In clinical trials, risankizumab produced endoscopic improvement (visible healing on a scope) in about 32% to 40% of patients after induction, compared to 12% on placebo. Guselkumab showed similar results. For people who’ve already tried and failed an anti-TNF drug, risankizumab is now preferred over ustekinumab, an older drug that blocks a broader immune target.
There are also gut-selective therapies that work by preventing inflammatory immune cells from migrating into intestinal tissue, plus a newer class of oral medications (JAK inhibitors) that interrupt inflammatory signaling inside cells. Your gastroenterologist will match the drug to your disease pattern, severity, and treatment history.
How Your Disease Gets Monitored
You don’t always need a colonoscopy to check whether your disease is active. A stool test measuring a protein called fecal calprotectin can help. A level below 150 micrograms per gram, combined with normal blood inflammation markers, is generally enough to confirm that inflammation is under control without scoping. If your calprotectin rises above 150, your doctor will likely recommend a colonoscopy to see what’s happening directly rather than just adjusting your medications blindly.
After surgery, guidelines now recommend an endoscopic check at 6 to 12 months to catch recurrence early, even if you feel fine. Crohn’s has a tendency to return at the surgical site, and catching it before symptoms appear gives treatment the best chance of working.
Diet as a Management Tool
Diet alone won’t replace medication for most people, but it plays a real role, especially in milder disease. The 2025 guidelines specifically recognize Mediterranean and specific carbohydrate diets as options for low-risk patients with mild Crohn’s, based on trial data, though close monitoring is important.
The Crohn’s Disease Exclusion Diet (CDED) has the strongest research behind it. It works in phases: the first six weeks are highly restrictive, cutting out foods thought to trigger intestinal inflammation while emphasizing lean proteins like chicken and eggs, resistant starches from potatoes, and pectin-rich fruits like bananas and apples. These foods are chosen specifically to support beneficial gut bacteria. In adult studies, the CDED produced clinical remission in 57% to 77% of patients after six weeks, and up to 82% after 12 weeks. When combined with partial enteral nutrition (supplemental liquid formula), remission rates reached 68% at six weeks with tolerability that was better than an all-liquid diet.
During a severe flare, your doctor may recommend exclusive enteral nutrition (EEN), a complete liquid diet using a specialized formula. This is first-line therapy for children with Crohn’s and sometimes used in adults. You consume only the formula, either by drinking it or through a thin tube from the nose to the stomach, for one to three months. Clear fluids like water, broth, popsicles, and sports drinks are allowed alongside it. Once the course is complete, solid foods are reintroduced gradually. EEN works partly by resting the gut and partly by changing the intestinal environment in ways that reduce inflammation.
Nutritional Deficiencies to Watch For
Crohn’s disease disrupts nutrient absorption, especially when the small intestine is involved. Up to 90% of patients have low levels of certain antioxidants even during inactive disease, and about half are deficient in zinc, selenium, magnesium, or vitamin C.
Three deficiencies deserve particular attention. Iron deficiency is common due to both poor absorption and intestinal blood loss. Vitamin D deficiency is frequent and matters because it affects bone density, which is already at risk from steroid use. People with Crohn’s who can’t absorb vitamin D well through the gut may need higher doses, sometimes 2,000 to 4,000 IU daily or periodic high-dose supplements. Vitamin B12 is absorbed only in the terminal ileum, the exact stretch of intestine Crohn’s most commonly affects. If that section is diseased or has been surgically removed, oral B12 won’t work and injections become necessary. Regular blood work to check these levels should be part of your routine care.
Stress and Mental Health
Stress doesn’t cause Crohn’s, but it can trigger flares and make symptoms harder to cope with. A meta-analysis of randomized controlled trials found that cognitive behavioral therapy (CBT) significantly improved quality of life scores in people with inflammatory bowel disease, with the benefit most clear in programs lasting 12 weeks or longer. CBT also reduced anxiety and depression. If you notice that stress reliably precedes your flares, or if anxiety about the disease itself is affecting your daily life, structured psychological support is a legitimate part of your treatment plan, not an add-on.
Vaccines and Infection Prevention
Many Crohn’s medications suppress parts of the immune system, which means you need to be strategic about vaccines. The key rule: no live vaccines once you’ve started immunosuppressive therapy. This includes the live versions of vaccines for measles, mumps, rubella, varicella, and certain others. If you stop a biologic, you generally need to wait at least three months before receiving a live vaccine. For steroids at higher doses, the wait is at least one month after stopping.
Ideally, your vaccination status gets updated before starting immunosuppressive treatment. Inactivated vaccines (like the flu shot and COVID vaccines) remain safe while on these medications, though your immune response may be slightly weaker. Talk to your gastroenterologist about a vaccination plan early in your treatment.
What Surgery Looks Like
Surgery isn’t a failure of treatment. It’s sometimes the best option, particularly for strictures (narrowed sections of intestine), fistulas that don’t respond to medication, or abscesses. The most common procedure removes the diseased segment and reconnects the healthy ends. For fistulizing disease, the first-line medical option is an anti-TNF drug, but several newer biologics and JAK inhibitors are now considered reasonable alternatives.
After surgery, the focus shifts to prevention. High-risk patients are typically started on a biologic to reduce the chance of recurrence, and endoscopic monitoring at 6 to 12 months helps catch any early signs of disease returning at the surgical site. Postoperative management has become more proactive in recent years, reflecting the understanding that Crohn’s almost always recurs without preventive therapy.